167 related articles for article (PubMed ID: 7254439)
1. The macrophage electrophoretic mobility assay in patients with renal cell carcinoma.
Malkovský M; Bubeník J; Jakoubková J; Suhajová E; Indrová M; Jandlová T; Símová J
Neoplasma; 1981; 28(2):245-51. PubMed ID: 7254439
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte sensitization detected by the macrophage electrophoretic mobility assay in patients with renal cell carcinoma: Theophylline increases the sensitivity of the assay.
Malkovský M; Bubeník J; Malkovská V; Indrová M; Suhajová E; Jakoubková J; Jíra M
Arch Geschwulstforsch; 1981; 51(4):364-70. PubMed ID: 7032451
[TBL] [Abstract][Full Text] [Related]
3. Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma.
Hemstreet GP; Dawson JR; Seigler HF
Cancer Res; 1978 May; 38(5):1447-56. PubMed ID: 646859
[TBL] [Abstract][Full Text] [Related]
4. [Reaction of inhibition of macrophage electrophoretic mobility in differential diagnosis of carcinomas].
Miuller M; Irmsher Iu; Fisher R; Grosmann G
Vopr Onkol; 1976; 22(12):43-50. PubMed ID: 1020256
[TBL] [Abstract][Full Text] [Related]
5. Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease.
Light PA; Preece AW; Waldron HA
Clin Exp Immunol; 1975 Nov; 22(2):279-84. PubMed ID: 55328
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the macrophage electrophoretic mobility test and the leukocyte migration inhibition test in the detection of histocompatibility antigens on tumor cells.
Bubeník J; Cochran AJ; Todd G; Malkovský M; Jandlová T; Suhajová E; Boubelík M
Neoplasma; 1981; 28(2):185-93. PubMed ID: 7019742
[TBL] [Abstract][Full Text] [Related]
7. The macrophage electrophoretic migration (MEM) test for lymphocyte sensitization. A study of the kinetics.
Carnegie PR; Caspary EA; Dickinson JP; Field EJ
Clin Exp Immunol; 1973 May; 14(1):37-45. PubMed ID: 4716103
[TBL] [Abstract][Full Text] [Related]
8. [Determination of the MSF (macrophage slowing factor) release by phytohemagglutinin using the macrophage electrophoretic mobility test (MEM test). I. Dependency of release on incubation time, phytohemagglutinin and cell concentration].
Metzner G; Jäger L
Acta Biol Med Ger; 1980; 39(2-3):223-7. PubMed ID: 6999821
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of normal mouse lymphocytes immunized in vitro as detected by macrophage electrophoretic mobility (MEM) test.
Nĕmecková S; Bubeník J; Indrová M
Folia Biol (Praha); 1982; 28(4):280-2. PubMed ID: 7141039
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a soluble tumor-associated antigen from human renal cell carcinoma by gradient acrylamide gel electrophoresis.
Wright GL; Schellhammer PF; Faulconer RL
Cancer Res; 1977 Nov; 37(11):4228-32. PubMed ID: 911404
[No Abstract] [Full Text] [Related]
11. The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors.
Preece AW; Light PA
Clin Exp Immunol; 1974 Dec; 18(4):543-52. PubMed ID: 4143199
[TBL] [Abstract][Full Text] [Related]
12. The use of the macrophage electrophoretic mobility test for the diagnosis of eye diseases.
Jenssen R; Jenssen HL; Köhler H; Friemel H
Mod Probl Ophthalmol; 1976; 16():259-64. PubMed ID: 943037
[TBL] [Abstract][Full Text] [Related]
13. [The macrophage electrophoretic mobility LAD test--a diagnostic method for multiple sclerosis (author's transl)].
Meyer-Rienecker H; Jenessen HL; Köhler H; Günther JK
J Neurol; 1976 Feb; 211(3):229-40. PubMed ID: 55489
[TBL] [Abstract][Full Text] [Related]
14. Reactivity of human lymphocytes to teratoma preparations as revealed by the macrophage electrophoretic mobility (MEM) technique.
Irmscher J; Grossmann H; Kotzsch M; Wagner H; Müller M
Arch Geschwulstforsch; 1982; 52(5):349-53. PubMed ID: 7149908
[TBL] [Abstract][Full Text] [Related]
15. [Suppression of leukocyte migration by autologous and allogeneic tumor extracts in kidney cancer patients].
Novikov DK; Borisenko ID; Shein IA
Vopr Onkol; 1978; 24(12):50-5. PubMed ID: 83731
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
18. [Cytopherometry in neurologic diseases (author's transl)].
Meyer-Rienecker HJ; Jenssen HL; Köhler H; Werner H
Fortschr Neurol Psychiatr Grenzgeb; 1977 Nov; 45(11):615-29. PubMed ID: 336499
[TBL] [Abstract][Full Text] [Related]
19. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
20. Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
Ishibashi M; Matsuda M; Osafune M; Nakano E; Fujioka H; Takaha M; Sonoda T; Kotake T; Watanabe S
Hinyokika Kiyo; 1983 Feb; 29(2):121-9. PubMed ID: 6677115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
